Idiopathic Pulmonary Fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults. IPF is a fatal disease with median survival at 3-5 years. While there exist several clinical approaches to treating IPF, few therapeutics have been clinically proven to provide significant benefits to patients. Eleven P15 is uniquely positioned for early detection and early intervention of IPF. The pivotal discovery of a common polymorphism in the promoter of MUC5B (rs35705950) has been associated with IPF and pulmonary fibrosis associated with rheumatoid arthritis, and this polymorphism increases the production of mucus.